Practical diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder by psychiatrists and obstetricians/gynecologists in Japan
Authors:
Open Access
- 15 August 2024
- journal article
- research article
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 3 (3) , e234
Abstract
Aim: To investigate and compare the diagnoses and treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) from the perspectives of psychiatrists and obstetricians/gynecologists (OB/GYNs) in Japan.Methods: Between December 2021 and February 2022, a web‐based survey was conducted among the members of the Japanese Association of Neuro‐Psychiatric Clinics. Data from 262 psychiatrists who responded to the aforementioned survey were compared with data from 409 OB/GYNs from a survey conducted in 2021 among members of the Japanese Society of Obstetrics and Gynecology.Results: Overall, 79.8% of psychiatrists and 97.3% of OB/GYNs were involved in practicing PMS/PMDD diagnosis and treatment. Most psychiatrists believed that PMS should be treated by OB/GYNs (74.4%) and PMDD by psychiatrists (75.6%). Only vague medical interviews were conducted by 86.6% of psychiatrists, and only 9.7% maintained a two‐cycle symptom diary. Psychiatrists mostly prescribed selective serotonin/serotonin and noradrenaline reuptake inhibitor (SSRI/SNRI) continuous dosing (91.1%), followed by Kampo medicines, especially Kamishoyosan (73.3%); only 2.8% chose oral contraceptive pills, unlike OB/GYNs, while SSRI continuous (32.8%) and luteal phase dosing (20.6%) and Kampo medicine (42.1%) were the most common first‐line treatments. Lifestyle guidance was prescribed by 63.6% of psychiatrists, followed by cognitive behavioral therapy (13.8%) and the symptom diary observation method (11.1%), which were similar to OB/GYNs' choices.Conclusions: Many Japanese psychiatrists and OB/GYNs do not base PMS/PMDD diagnoses on prospective monitoring methods using specific diagnostic criteria and therefore do not provide evidence‐based treatment. Moreover, a tendency of being biased toward treatments in which the department specialized was observed.Keywords
This publication has 30 references indexed in Scilit:
- Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorderArchives of Women's Mental Health, 2016
- Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric DisorderJAMA Psychiatry, 2015
- ISPMD consensus on the management of premenstrual disordersArchives of Women's Mental Health, 2013
- Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensusArchives of Women's Mental Health, 2011
- Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic reviewArchives of Women's Mental Health, 2009
- Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese womenArchives of Women's Mental Health, 2006
- Daily Record of Severity of Problems (DRSP): reliability and validityArchives of Women's Mental Health, 2005
- The premenstrual symptoms screening tool (PSST) for cliniciansArchives of Women's Mental Health, 2003
- Alprazolam in the Treatment of Premenstrual SyndromeArchives of General Psychiatry, 1993
- Treatment of Premenstrual Dysphoria With AlprazolamArchives of General Psychiatry, 1990